A multi-dimensional approach to lichen sclerosus therapy

Luigi Laino12*

1Dermatologic and Venereologic Centre Via Bixio, Rome, Italy
2Faculty at Dermatologic Institute for Research and Care – IRCCS, Rome Italy

Lichen sclerosus (LS) [1,2,3] is an inflammatory dermatologic condition characterized by a potential for atrophy, hypertrophy, destructive scarring, functional impairment, leucoplaclia, and malignant evolution [4]. Therefore, early diagnosis, prompt treatment, and long-term follow-up are mandatory. Spontaneous remissions are rare. Despite there isn’t a causal therapy, LS can be controlled by adequate treatment: in several cases, it could be observed a complete remission of signs and symptoms. With early treatment, long-term sequelae such as destruction of anatomic structures and progression to squamous cell carcinoma may be prevented. In particular cases, could be very useful that a multi-disciplinary approach, so is necessary that dermatologists, urologists and gynecologists have a solid knowledge of the disease and will not hesitate to cooperate if required. Since LS begins with uncharacteristic symptoms, a peculiar clinical examination, and if necessary, a histopathologic confirmation is required. Despite many efforts have been made, in recent years, to find an appropriate therapy that could cure effectively lichen sclerosus, there are many treatment failures. While many cases of LS must not be treated surgically, it is also true, that many LS are due to congenital or acquired alterations that caused the persistence of the disease; this anatomical changes can be identified as "trigger factors" for the auto-maintenance of LS signs and symptoms; in this occasion, only topical and/or micro-infiltrative approach could be insufficient for a long-term management and could delay or making inadequate the only topical and/or micro-infiltrative approaches. For this reason we have developed, over 6 year (2008 to present) in 58 patients (36 male, 22 female aged from 28 from 65 year-old suffering from moderate to severe lichen sclerosus, a multi-dimensional protocol that is based the following triad: conservative surgical therapy, topical therapy and micro-infiltrative therapy. We made a diagnosis of LS, both on the basis of clinical data and through biopsy, in compliance with the recent guidelines of the British Association of Dermatologists [5]. The patients were evaluated by the investigator on the Investigator’s Global Assessment (IGA) and the Dermatology Life Quality Index (DLQ) [6].

We divided our patients into 2 groups, A (=16; male=8; female=8) and B (=16; male=8; female=8), with homogeneous IGA and DLQI.

For group A patients, we proposed a multi-dimensional therapeutic approach that consisted in:

a) Conservative dermosurgical approach, limited to eliminate peculiar alteration as the presence of a short and sclerotic frenulum, partial or total sclerotic phimosis, balano-preputial/vulvar synchiae or leucoplastic areas, associated to histological exam.

b) Topical Therapy with clobetasolpropionate (CP) + Vit E emollient cream

c) Subdermal micro-infiltration with polydeoxyribonucleotide (PDRN)

For group B, we proposed a single therapy with

a) ultra-potent steroid cream (clobetasol propionate + Vit E emollient cream)

All patients gave their informed consent to the treatment after an exhaustive explanation of effects, side or unwanted effects, especially related to surgery, ultrapotent corticosteroid topical application or topical immune-modulators, and (in our cases) subdermal administration of Polydeoxyribonucleotide (PDRN) [7].

At the end of the therapeutic sessions, all group A patients (n=16) experienced a significant improvement of the condition as shown in Table 1. All group B patients showed only moderate clinical improvements. After therapy, a statistically significant reduction of the score was found in both groups (Table 1).

There were no other adverse reactions in other group A and group B patients. All patients have shown normal serologic parameters, before, during, and after therapy. The results obtained in group A were maintained until last clinical control (6 months after), while some patients of group B (n=9) have demonstrated slight to moderate representation of pathologic signs, 4–6 months after the end of therapy.

In the light of these results, we sustain that the most important anatomical and functional abnormalities, that we believe may delay or prevent the benefits of an effective therapy, and in which we performed a dermatologic conservative surgical treatment are:

In men:
- The presence of a short and sclerotic frenulum
- The presence of a partial or total sclerotic phimosis
- The presence of balano-preputial/synchiae

In women:
- The presence of a vaginal synchiae (which reduces the vulvar orifice and causes continuous post coital lacerations)

For both sex:
- The presence of leucoplastic infiltrative areas

Many of these acquired anatomical and functional alterations can compete with the persistence of the disease and treatment failures. In addition, there is the evidence that some lesions of LS, often appear...

Correspondence to: Dr. Luigi Laino, Director of Dermatologic and Venereologic Centre Via Bixio, Rome, Italy, Tel: +390645550661; Fax: +390690213462; E-mail: luigilaino@yahoo.it

Key words: Lichen sclerosus, phimosis, neoplastic vulvar condition

Received: March 10, 2015; Accepted: April 11, 2015; Published: April 13, 2015
Figure 1. Notice, the significant improvement of Lichen sclerosus signs after combined therapy (ex. A: pre-therapy; A1: post-therapy).

Table 1. Values (median) of IGA and DLQI scores before and after therapy in group A and group B; comparisons are evaluated using paired Wilcoxon signed-rank for paired data.

| Variables      | Group A   | Group B   | P value |
|---------------|-----------|-----------|---------|
|               | Beforetherapy | Aftertherapy |       | Beforetherapy | Aftertherapy |       |
| IGA Median (range) | 6 (3–10) | 2 (0–7) | 0.001 | 5 (1–9) | 4 (2–6) | 0.001 |
| DLQI Median (range) | 15 (8–19) | 7 (3–11) | 0.001 | 14 (8–19) | 11 (6–16) | 0.003 |

The choice of topical therapy should, always fall back on a medium to high potential steroidal drug, or topical immunomodulators according to the last published guidelines about LS. Is also useful, to conduct a micro-infiltrative therapy, with PRP or with Polydeoxyribonucleotide, in order to contribute in tissue regenerative approach already affected by the disease. We use in all selected cases, Polydeoxyribonucleotide (PDRN) subdermal-infiltrations, following the guidelines of our protocol [8,9]. Thanks to this therapeutic triad, we have achieved in all our patients, significant (p<0.001) decrease of IGA and DLQI (Table 1) even in case of severe LS; these clinical results (Figure 1), were maintained at a distance of months from the suspension of the therapy.

Despite many therapeutic approaches proposed over the years, the definitive treatment of lichen sclerosus is still being codified. We believe that a viable therapy consists of a multidisciplinary approach that is based on proper clinical staging and histological diagnosis. We maintain that a valid therapeutic proposal is not confined to a drug, but to a therapeutic set and to a proper therapeutic approach, based on the type and the severity degree of the disease. In this context, through this preliminary study, we have highlighted the efficacy, tolerability, and safety profile demonstrated by a therapeutic dermatologic triad, which could be cited, (if further studies confirm these early data) as one of the effective management of lichen sclerosus.

References
1. Cavelier-Balloy B (2012) Lichen sclerosus. Ann Dermatol Venereol 139: 65-67. [Crossref]
2. Lù J, Huang XD (2014) Current diagnosis and treatment of male genital lichen sclerosus. Zhonghua Nan Ke Xue 20: 579-585. [Crossref]
3. Fistarol SK, Itin PH (2013) Diagnosis and treatment of lichen sclerosus: an update. Am J Clin Dermatol 14: 27-47. [Crossref]
4. Brady KL, Mercurio MG, Brown MD (2013) Malignant tumors of the penis. Dermatol Surg 39: 527-547. [Crossref]
5. Neill SM, Lewis FM, Tnatall FM, Cox NH (2010) British association of dermatologists’ guidelines for the management of lichen sclerosus 2010. Br J Dermatol 163: 672-682. [Crossref]
6. Finlay AY, Khan GK (1994) Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol 19: 210-216. [Crossref]
7. Bitto A, Polito F, Ierera N, D’Ascola A, Avveneto A, et al. (2011) Polydeoxyribonucleotide reduces cytokine production and the severity of collagen-induced arthritis by stimulation of adenosine A2A receptor. Arthritis Rheum 63: 3364–3371. [Crossref]
8. Laino (2012) Adjuvant clinical effects of polydeoxyribonucleotide in lichen sclerosus. Eur J Dermatol 22: 575–576. [Crossref]
9. Laino L, Suetti S, Sperduti I (2013) Polydeoxyribonucleotide Dermal Infiltration in Male Genital Lichen Sclerosus: Adjuvant Effects during Topical Therapy. Dermatol Rev Prac 2013: 654079.